Merck at ASCO 2025
We’re developing more than 20 novel treatment mechanisms with the goal of improving the lives of more people living with more types of cancer.
The American Society of Clinical Oncology (ASCO) creates space to collaborate and celebrate what we’re doing as a community united to transform the way cancer is treated. Our presence at ASCO 2025 underscores our unwavering commitment to oncology as we continue to diversify and strengthen our pipeline and portfolio.
Read our ASCO 2025 press releases
“Our goal is simple: help more people living with cancer with more targeted approaches.”
-- Dr. Marjorie Green
Head of oncology clinical developmentOur commitment to oncology
We chase bold goals by relentlessly searching for the next breakthrough in treating cancer — driven by science, guided by need and inspired by the lives we aim to prolong and protect.
We’re researching more than 30 different types of cancer as we work to develop treatments that may improve outcomes for patients, no matter what stage of cancer they have. With one of the largest oncology development programs in the industry, including more than 20 novel treatment mechanisms in late-stage development, we’re committed to shaping the future of cancer care and bringing innovation to the people who need it most.
Pursuing breakthrough science
Our work in oncology goes beyond the lab bench. Every day, our teams are driven by a deep commitment to answering tough questions about one of the world’s most complex diseases.
Media library/contacts
Global media relations may only answer inquiries from members of the media, and our assets intended for use by media professionals. If you're a journalist, please contact the appropriate team member or team below.
For media professionals only
Corporate and scientific media inquiries
